EZH2 and breast cancer: To test these, we stratified ET-treated ER+ breast cancer patients for a G9a-EZH2-KMT5C signature and observed that patients with low expression have a significantly lower risk of relapse over the course of 15 to 20 years as compared with high expressors (Fig. 6G; and Supplementary Fig. S27A and S27B).